🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

842 results for “Eli” Clear

  1. TOOKAD 183 mg powder for solution for injection, PADELIPORFIN

    STEBA Biotech S.A

    Low Grade Upper Tract Urothelial Cancer

    phase 3 small molecule active

    1 trial

  2. TOPOTECAN HYDROCHLORIDE, DOXORUBICIN HYDROCHLORIDE, PACLITAXEL, KEYTRUDA 25 mg/mL concentrate for solution for infusion, NEMVALEUKIN ALFA, GEMCITABINE HYDROCHLORIDE, TOPOTECAN HYDROCHLORIDE

    Ology Bioservices Ireland LTD

    Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

    phase 3 small molecule active

    1 trial

  3. TRASTUZUMAB, Tislelizumab, Oxaliplatin 5 mg/ml concentrate for solution for infusion, LOPERAMIDE, JZP598, CAPECITABINE

    Jazz Pharmaceuticals Ireland Limited

    Gastroesophageal Adenocarcinoma (GEA)

    phase 3 small molecule active

    1 trial

  4. TROPICAMIDE, Vehicle for cenegermin drug product, COLIROFTA ANESTÉSICO DOBLE 1 MG/ML + 4 MG/ML COLIRIO EN SOLUCIÓN, OXERVATE 20 micrograms/ml eye drops, solution

    Dompe' Farmaceutici S.p.A.

    Persistent Corneal Epithelial Defect (PCED)

    phase 3 small molecule active

    1 trial

  5. Telisotuzumab Vedotin, DOCETAXEL

    AbbVie Deutschland GmbH & Co. KG

    c-Met overexpressing EGFR wildtype non-squamous non-small cell lung cancer

    phase 3 small molecule active

    1 trial

  6. Telitacicept

    Vor Biopharma

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

  7. Telitacicept

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  8. Telitacicept

    Vor Biopharma

    Primary Sjogren's Disease

    phase 3 mab active

    1 trial

  9. Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age

    SINOVAC BIOTECH LTD

    Poliomyelitis

    phase 3 mab completed

    1 trial

  10. Tinlarebant 5 mg´s matching Placebo, LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Stargardt Disease

    phase 3 small molecule active

    1 trial

  11. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Mirikizumab, Mirikizumab, to match Tirzepatide, Tirzepatide, Mirikizumab, Tirzepatide

    Eli Lilly Co.

    Obesity or Overweight, Crohn’s Disease

    phase 3 small molecule active

    1 trial

  12. Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Tirzepatide, Placebo to match LY3298176 injection

    Eli Lilly Co.

    Obesity

    phase 3 small molecule active

    1 trial

  13. Tislelizumab

    China SXT Pharmaceuticals

    Locally Advanced Rectal Carcinoma

    phase 3 small molecule active

    1 trial

  14. Tislelizumab

    Beone Medicines Ireland Limited

    Classical Hodgkin Lymphoma

    phase 3 small molecule terminated

    1 trial

  15. Tislelizumab

    China SXT Pharmaceuticals

    Colonic Neoplasms

    phase 3 small molecule active

    1 trial

  16. Tislelizumab

    Beone Medicines Ireland Limited

    Non Small Cell Lung Cancer

    phase 3 small molecule active

    4 trials

  17. Tislelizumab

    First Tracks Biotherapeutics

    Rectal Neoplasms

    phase 3 small molecule active

    1 trial

  18. Tislelizumab

    Beone Medicines Ireland Limited

    Urothelial Carcinoma

    phase 3 small molecule active

    1 trial

  19. Tislelizumab

    Beone Medicines Ireland Limited

    Esophageal Squamous Cell Carcinoma (ESCC)

    phase 3 small molecule completed

    1 trial

  20. Tislelizumab

    Beone Medicines Ireland Limited

    Advanced Malignancies

    phase 3 small molecule active

    1 trial

  21. Tislelizumab + SOX Chemotherapy

    First Tracks Biotherapeutics

    Gastric Cancer Stage III

    phase 3 small molecule active

    1 trial

  22. Tislelizumab 300 mg solution for injection, Tevimbra 100 mg concentrate for solution for infusion

    Beone Medicines Ireland Limited

    Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma

    phase 3 small molecule active

    1 trial

  23. Tislelizumab（neoadjuvant）

    China SXT Pharmaceuticals

    Head and Neck Squamous Cell Carcinomas

    phase 3 small molecule active

    1 trial

  24. Tocilizumab, Placebo to match 2 mg/mL oral suspension, BARICITINIB, Baricitinib, Placebo to match 4 mg tablet, TOCILIZUMAB , Placebo to match 2 mg tablet, JAK1/JAK2 inhibitor, Placebo to match 1 mg tablet, BARICITINIB

    Eli Lilly Co.

    Systemic Juvenile Idiopathic Arthritis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources